文献速递白血病

共转录剪接破坏提示RBM39是急性淋巴细胞白血病的治疗靶点

Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2024-01-01

研究揭示RBM39中毒性外显子可被CMGC激酶抑制或CDK9抑制诱导纳入,经无义介导的mRNA衰减通路降解,导致蛋白下调并抑制急性淋巴细胞白血病生长,尤其在复发/难治性B-ALL中;磺胺类药物降解RBM39在临床前模型中显示强抗肿瘤活性。

要点

  • 抑制CMGC激酶或CDK9可诱导RBM39中毒性外显子纳入,经NMD降解RBM39蛋白。
  • RBM39敲低抑制人B-ALL生长,磺胺类药物降解RBM39在临床前模型显示强抗肿瘤活性。
  • 复发/难治性B-ALL对RBM39的药理和遗传抑制敏感,提供两种潜在靶向策略。

核心结论

  • 复发/难治性B-ALL对RBM39的药理和遗传抑制敏感,靶向RBM39轴提供两种潜在策略。

研究设计与样本

  • 本研究为实验室研究,涉及RBM39中毒性外显子纳入机制及CMGC激酶抑制、CDK9抑制和磺胺类药物降解RBM39的临床前模型。

主要发现

  • 抑制CMGC激酶(包括DYRK1A)或CDK9可改变SF3B1与Pol II关联,破坏共转录剪接,改变Pol II暂停,促进RBM39中毒性外显子纳入。
  • RBM39中毒性外显子纳入后被无义介导的mRNA衰减通路识别并降解,导致蛋白下调并抑制ALL生长,尤其在复发/难治性B-ALL中。
  • RBM39敲低抑制人B-ALL生长,磺胺类药物降解RBM39蛋白在临床前模型中显示强抗肿瘤活性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are only a few options for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), thus, this is a major area of unmet medical need. In this study, we reveal that the inclusion of a poison exon in RBM39, which could be induced by both CDK9 or CDK9 independent cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, CDC-like kinases (CMGC) kinase inhibition, is recognized by the nonsense-mediated messenger RNA decay pathway for degradation. Targeting this poison exon in RBM39 with CMGC inhibitors led to protein downregulation and the inhibition of ALL growth, particularly in relapsed/refractory B-ALL. Mechanistically, disruption of cotranscriptional splicing by the inhibition of CMGC kinases, including DYRK1A, or inhibition of CDK9, which phosphorylate the C-terminal domain of RNA polymerase II (Pol II), led to alteration in the SF3B1 and Pol II association. Disruption of SF3B1 and the transcriptional elongation complex altered Pol II pausing, which promoted the inclusion of a poison exon in RBM39. Moreover, RBM39 ablation suppressed the growth of human B-ALL, and targeting RBM39 with sulfonamides, which degrade RBM39 protein, showed strong antitumor activity in preclinical models. Our data reveal that relapsed/refractory B-ALL is susceptible to pharmacologic and genetic inhibition of RBM39 and provide 2 potential strategies to target this axis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jin Q, Harris E, Myers JA, et al. Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia. Blood. 2024. PMID: 39316649. doi:10.1182/blood.2024024281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。